You are here

Clinical Trials: Central Nervous System Diseases

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Friday, September 23, 2022 - 12:00
Conditions:   Spinal Cord Injuries;   Tetraplegia
Intervention:   Device: Testing of MyHand-SCI Device
Sponsors:   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
Posted: Thursday, September 15, 2022 - 12:00
Condition:   Progressive Multifocal Leukoencephalopathy
Intervention:   Biological: CE-VST01-JC
Sponsor:   Cellevolve Bio Inc
Not yet recruiting
Posted: Wednesday, August 24, 2022 - 12:00
Conditions:   Hypoxic-Ischemic Encephalopathy;   Neonatal Asphyxia;   Neonatal Encephalopathy
Interventions:   Drug: Normal Saline along with standard treatment;   Drug: Sovateltide along with standard treatment
Sponsor:   Pharmazz, Inc.
Not yet recruiting
Posted: Thursday, August 11, 2022 - 12:00
Condition:   Brain Concussion
Intervention:   Behavioral: Aerobic Exercise
Sponsors:   State University of New York at Buffalo;   United States Department of Defense;   Children's Hospital of Philadelphia;   University of Pennsylvania;   University of North Carolina, Chapel Hill;   Geneva Foundation;   Quadrant Biosciences Inc.;   Center for Neuroscience and Regenerative Medicine (CNRM);   Axon Medical Technologies LLC
Not yet recruiting
Posted: Tuesday, June 28, 2022 - 12:00
Condition:   Parkinson's Disease
Interventions:   Biological: hAESCs treatment;   Biological: placebo (saline)
Sponsors:   Shanghai East Hospital;   Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Not yet recruiting
Posted: Thursday, April 7, 2022 - 12:00
Condition:   Frontotemporal Dementia
Intervention:   Drug: ET-STEM
Sponsor:   Samsung Medical Center
Not yet recruiting
Posted: Friday, April 1, 2022 - 12:00
Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Biological: CNS10-NPC-GDNF
Sponsors:   Cedars-Sinai Medical Center;   California Institute for Regenerative Medicine (CIRM)
Posted: Thursday, March 31, 2022 - 12:00
Condition:   Moderate to Severe Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting
Posted: Wednesday, March 23, 2022 - 12:00
Condition:   Ischemic Stroke
Interventions:   Biological: UC-MSC infusion via intravenous route;   Biological: UC-MSC infusion via intrathecal route;   Other: standard stroke treatment and rehabilitation therapy
Sponsor:   Vinmec Research Institute of Stem Cell and Gene Technology
Posted: Wednesday, January 12, 2022 - 12:00
Condition:   Mild to Moderate Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting